Another short-term goal for Attana is to become cash flow positive. To balance revenues and costs is the foundation of all sustainable businesses, and we need to take decisions in line with that strategy. Concurrently, we are restructuring our customer relationships and defining clearer roles and responsibilities internally while reviewing our cost level. Commercially, we are focusing on five revenue streams: CRO, instrument sales, service, consumables, and immunity profiles. The first four are related to our traditional Life Science business and will be the backbone of our business in the coming year. The fifth revenue stream, the immunity profiles, is connected to Diagnostics and defined as our growth market.

Shortly, I will participate in a podcast where I will share my views and ideas on how to stabilize and grow our business. We will share the event in our social media channels in mid-October.

Our technology and the IP we hold is world-leading but also underestimated by markets and certain conservative competitors and customers. I can understand that, but I can't accept it. We shall work hard to convince the market differently. As a team, we shall be present and assist our customers in their highly important projects, exceed their expectations and solve their scientific problems continuously. More than 150 publications and the outcome from our customers' clinical trials sends a clear message, the drug development process can be improved and yet more cost efficient with our technology. Additionally, increased cost savings for hospitals through more precise diagnostics, and an improved understanding among citizens regarding their own vaccine protection is very beneficial for the society but not yet addressed.

Thank you for being an important part of our global community.

Best regards,

Marcus Söderberg
CEO, Attana